Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 384

1.

Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.

Zhou XF, Yang X, Wang Q, Coburn RA, Morris ME.

Drug Metab Dispos. 2005 Aug;33(8):1220-8. Epub 2005 May 20.

3.

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.

Cancer Res. 2005 Feb 15;65(4):1541-6.

4.

BCRP transports dipyridamole and is inhibited by calcium channel blockers.

Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD, Mao Q.

Pharm Res. 2005 Dec;22(12):2023-34. Epub 2005 Nov 1.

PMID:
16247709
5.

Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.

Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S.

Int J Cancer. 2004 Jan 1;108(1):146-51.

6.

Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.

Zhang S, Yang X, Morris ME.

Mol Pharmacol. 2004 May;65(5):1208-16.

7.

Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.

Imai Y, Tsukahara S, Asada S, Sugimoto Y.

Cancer Res. 2004 Jun 15;64(12):4346-52.

8.

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, Schinkel AH.

Mol Cancer Ther. 2002 Apr;1(6):417-25.

10.

Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.

Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T.

Mol Cancer Ther. 2003 Jan;2(1):105-12.

11.

The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2.

Shukla S, Robey RW, Bates SE, Ambudkar SV.

Biochemistry. 2006 Jul 25;45(29):8940-51.

PMID:
16846237
12.

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH.

J Natl Cancer Inst. 2000 Oct 18;92(20):1651-6.

PMID:
11036110
13.
14.

Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.

Robey RW, Medina-PĂ©rez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE.

Clin Cancer Res. 2001 Jan;7(1):145-52.

15.

Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.

Elahian F, Kalalinia F, Behravan J.

Drug Chem Toxicol. 2010 Apr;33(2):113-9. doi: 10.3109/01480540903390000.

PMID:
20307139
16.

[Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].

Zhang YH, Li G, Yu J, Xu MS, Liu ZX.

Zhonghua Zhong Liu Za Zhi. 2011 Sep;33(9):654-60. Chinese.

PMID:
22340044
17.

Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.

Zhang Y, Wang H, Wei L, Li G, Yu J, Gao Y, Gao P, Zhang X, Wei F, Yin D, Zhou G.

Breast Cancer Res Treat. 2010 Oct;123(3):679-89. doi: 10.1007/s10549-009-0660-2. Epub 2009 Dec 6.

PMID:
19967559
18.

Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.

Katayama K, Masuyama K, Yoshioka S, Hasegawa H, Mitsuhashi J, Sugimoto Y.

Cancer Chemother Pharmacol. 2007 Nov;60(6):789-97. Epub 2007 Mar 8.

PMID:
17345086
19.

Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.

Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q.

Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83. Epub 2006 Jan 11.

PMID:
16404634
20.

Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH.

Cancer Res. 1999 Sep 15;59(18):4559-63.

Supplemental Content

Support Center